Silencing ataxin-3 mitigates degeneration in a rat model of Machado-Joseph disease: no role for wild-type ataxin-3?
- PMID: 20308049
- DOI: 10.1093/hmg/ddq111
Silencing ataxin-3 mitigates degeneration in a rat model of Machado-Joseph disease: no role for wild-type ataxin-3?
Abstract
Machado-Joseph disease or spinocerebellar ataxia type 3 (MJD/SCA3) is a fatal, autosomal dominant disorder caused by a cytosine-adenine-guanine expansion in the coding region of the MJD1 gene. RNA interference has potential as a therapeutic approach but raises the issue of the role of wild-type ataxin-3 (WT ATX3) in MJD and of whether the expression of the wild-type protein must be maintained. To address this issue, we both overexpressed and silenced WT ATX3 in a rat model of MJD. We showed that (i) overexpression of WT ATX3 did not protect against MJD pathology, (ii) knockdown of WT ATX3 did not aggravate MJD pathology and that (iii) non-allele-specific silencing of ataxin-3 strongly reduced neuropathology in a rat model of MJD. Our findings indicate that therapeutic strategies involving non-allele-specific silencing to treat MJD patients may be safe and effective.
Similar articles
-
Striatal and nigral pathology in a lentiviral rat model of Machado-Joseph disease.Hum Mol Genet. 2008 Jul 15;17(14):2071-83. doi: 10.1093/hmg/ddn106. Epub 2008 Apr 1. Hum Mol Genet. 2008. PMID: 18385100
-
Silencing mutant ataxin-3 rescues motor deficits and neuropathology in Machado-Joseph disease transgenic mice.PLoS One. 2013;8(1):e52396. doi: 10.1371/journal.pone.0052396. Epub 2013 Jan 22. PLoS One. 2013. PMID: 23349684 Free PMC article.
-
A new humanized ataxin-3 knock-in mouse model combines the genetic features, pathogenesis of neurons and glia and late disease onset of SCA3/MJD.Neurobiol Dis. 2015 Jan;73:174-88. doi: 10.1016/j.nbd.2014.09.020. Epub 2014 Oct 7. Neurobiol Dis. 2015. PMID: 25301414
-
Polyglutamine diseases: the special case of ataxin-3 and Machado-Joseph disease.Prog Neurobiol. 2011 Sep 15;95(1):26-48. doi: 10.1016/j.pneurobio.2011.06.007. Epub 2011 Jun 28. Prog Neurobiol. 2011. PMID: 21740957 Review.
-
[Recent advances in molecular genetics of spinocerebellar ataxia type 3/Machado-Joseph disease].Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2008 Dec;25(6):660-2. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2008. PMID: 19065526 Review. Chinese.
Cited by
-
Lentiviral vector-mediated overexpression of mutant ataxin-7 recapitulates SCA7 pathology and promotes accumulation of the FUS/TLS and MBNL1 RNA-binding proteins.Mol Neurodegener. 2016 Jul 28;11(1):58. doi: 10.1186/s13024-016-0123-2. Mol Neurodegener. 2016. PMID: 27465358 Free PMC article.
-
Development of an AAV-Based MicroRNA Gene Therapy to Treat Machado-Joseph Disease.Mol Ther Methods Clin Dev. 2019 Oct 28;15:343-358. doi: 10.1016/j.omtm.2019.10.008. eCollection 2019 Dec 13. Mol Ther Methods Clin Dev. 2019. PMID: 31828177 Free PMC article.
-
Antisense gene silencing: therapy for neurodegenerative disorders?Genes (Basel). 2013 Sep 10;4(3):457-84. doi: 10.3390/genes4030457. Genes (Basel). 2013. PMID: 24705213 Free PMC article.
-
The Josephin domain (JD) containing proteins are predicted to bind to the same interactors: Implications for spinocerebellar ataxia type 3 (SCA3) studies using Drosophila melanogaster mutants.Front Mol Neurosci. 2023 Mar 15;16:1140719. doi: 10.3389/fnmol.2023.1140719. eCollection 2023. Front Mol Neurosci. 2023. PMID: 37008788 Free PMC article.
-
Targeting several CAG expansion diseases by a single antisense oligonucleotide.PLoS One. 2011;6(9):e24308. doi: 10.1371/journal.pone.0024308. Epub 2011 Sep 1. PLoS One. 2011. PMID: 21909428 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases